Bolt Biotherapeutics, Inc. (BOLT) — Financial statements
Income statement, balance sheet, and cash flow for Bolt Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 8↑0.1% | 8↓2.4% | 8↑37.5% | 6↑354.7% | 1 | |
| Cost of Revenue | 1 | 0.00↓100.0% | 62↓15.8% | 73↓3.3% | 76 | |
| Gross Profit | 6↓19.3% | 8↑114.3% | -54↑20.4% | -67↑9.4% | -74 | |
| Operating Expenses | ||||||
| R&D Expenses | 29↓50.4% | 57↓6.6% | 62↓15.8% | 73↓3.3% | 76 | |
| General & Administrative Expenses | 14↓25.3% | 18↓18.1% | 23↓1.7% | 23↑24.7% | 18 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↓25.3% | 18↓18.1% | 23↓1.7% | 23↑24.7% | 18 | |
| Other Expenses | -1↓131.0% | 5↑107.8% | -62↑15.8% | -73↑3.3% | -76 | |
| Operating Expenses | 41↓49.4% | 81↑258.4% | 23↓1.7% | 23↑24.7% | 18 | |
| Total Costs & Expenses | 42↓47.6% | 81↓4.0% | 84↓12.5% | 96↑2.1% | 94 | |
| Operating Results | ||||||
| Operating Income | -35↑52.6% | -73↑4.1% | -76↑15.6% | -90↑2.7% | -93 | |
| Depreciation & Amortization | 1↓16.3% | 2↓3.9% | 2↑11.3% | 2↑39.6% | 1 | |
| EBITDA | -33↑50.1% | -66↑10.6% | -74↑16.1% | -89↑3.2% | -92 | |
| EBIT | -35↑49.2% | -68↑10.4% | -76↑15.6% | -90↑2.7% | -93 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓52.5% | 5↓24.9% | 7↑214.8% | 2↑691.1% | 0.28 | |
| Interest Income | 2↓52.5% | 5↓24.9% | 7↑214.8% | 2↑691.1% | 0.28 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -5 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 1↓87.3% | 10↑41.9% | 7↑214.8% | 2↑138.3% | -6 | |
| Income Before Tax | -33↑47.1% | -63↑8.8% | -69↑21.5% | -88↑10.6% | -99 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -33↑47.1% | -63↑8.8% | -69↑21.5% | -88↑10.6% | -99 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -33↑47.1% | -63↑8.8% | -69↑21.5% | -88↑10.6% | -99 | |
| Bottom-Line Net Income | -33↑47.1% | -63↑8.8% | -69↑21.5% | -88↑10.6% | -99 | |
| EPS (Basic) | -17.85↓981.8% | -1.65↑9.8% | -1.83↑20.4% | -2.30↑17.6% | -2.79 | |
| EPS (Diluted) | -17.85↓981.8% | -1.65↑9.8% | -1.83↑20.4% | -2.30↑17.6% | -2.79 | |
| Weighted Average Shares | 2↓95.1% | 38↑1.0% | 38↑1.2% | 37↓0.1% | 37 | |
| Weighted Average Diluted Shares | 2↓95.1% | 38↑1.0% | 38↑1.2% | 37↓0.1% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.